Billionaire Profile
Marc Lipschultz
Global Rank
#2576

Image: Unsplash Contributor | Unsplash License | via Unsplash

Marc Lipschultz

CEO, Private equity
UNITED STATES
Real-Time Net Worth
$1.558B
Estimated based on Private equity stock value as of April 20, 2026
0% (24h)
Age
57
Source
Private equity
Industry
Finance & Investments
Citizenship
UNITED STATES

Biography

Marc Lipschultz is an American financier and business executive known for his significant contributions to the private equity sector. As the Co-Chief Executive Officer of Blue Owl Capital, he oversees an alternative asset management firm specializing in private credit and capital solutions. Lipschultz's net worth is estimated to be $1.6 Billion, primarily from his wealth source, private equity. His career includes pivotal roles at KKR & Co. and Goldman Sachs, which paved the way for his success in founding and leading Blue Owl Capital. Lipschultz, a graduate of Stanford University and Harvard Business School, is also actively involved in philanthropy, supporting various healthcare and educational initiatives.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life

Marc Lipschultz was born in the United States. Although specific details about his early life are not widely available, it is known that he attended Stanford University, where he earned a Bachelor's degree. He later received an MBA with high distinction as a Baker Scholar from Harvard Business School. Lipschultz also shared a Firestone Medal for his undergraduate research in economics.

Rise to Success

Lipschultz began his career in finance at Goldman Sachs before spending over two decades at KKR & Co. During his tenure at KKR, he served on the Management Committee and as the Global Head of Energy and Infrastructure, showcasing his expertise in investments and management. In 2016, Lipschultz co-founded Owl Rock Capital Partners, a predecessor firm to Blue Owl's Credit platform. The merger with Dyal Capital in 2021 led to the formation of Blue Owl Capital, where he currently serves as Co-Chief Executive Officer.

Key Business Strategies

Lipschultz has leveraged his extensive experience in private credit, private equity, and infrastructure to build Blue Owl Capital into a leading alternative asset management firm. His focus on permanent capital and innovative financing models has been instrumental in Blue Owl's growth, managing approximately $250 billion in assets. Key strategies include providing capital solutions for businesses through private credit and direct lending.

Philanthropy

Marc Lipschultz is actively involved in various nonprofit organizations. He serves on the boards of the American Enterprise Institute for Public Policy Research, the Michael J. Fox Foundation, Mount Sinai Health System, Riverdale Country School, Stanford University Board of Trustees, and the 92nd Street Y. He and his wife Jennifer have also made a multi-million dollar gift to the Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai. The institute has since been renamed the Marc and Jennifer Lipschultz Precision Immunology Institute.

Career Milestones

1991

Graduated from Stanford University

Earned a Bachelor of Arts degree in economics with honors and distinction.

1995

Graduated from Harvard Business School

Received an MBA with high distinction, as a Baker Scholar.

1995

Joined KKR & Co.

Began a long career at Kohlberg Kravis Roberts & Co., eventually becoming Global Head of Energy and Infrastructure.

2016

Cofounded Owl Rock Capital Partners

Co-founded Owl Rock Capital Partners, the predecessor firm to Blue Owl's Credit platform.

2021

Merger with Dyal Capital

Owl Rock merged with Dyal Capital to form Blue Owl Capital.

2023

Promoted to Co-CEO of Blue Owl Capital

Assumed the role of Co-Chief Executive Officer at Blue Owl Capital.

Philanthropy & Social Impact

Healthcare and Research

Precision Immunology Institute

$XB

Multi-million dollar gift to the Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai.